Contraceptive access gaps driven by federal rollbacks, provider shortages, and stalled state legislation could be narrowed by letting trained pharmacists prescribe birth control independently.
|Articles|August 10, 2022
Daily OTC Pearl: Aftera
Author(s)Saro Arakelians, PharmD
Aftera is an emergency contraceptive that reduces the chance of pregnancy after unprotected sex.
Advertisement
OTC/Lifestyle Pearl of the Day: Aftera
Indication: Aftera is an emergency contraceptive thatreduces the chance of pregnancy after unprotected sex.
Insight:
- Contains: Colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, potato starch, talc.
- Levonorgestrel 1.5mg
- Take as soon as possible within 72 hours after unprotected sex. The sooner you take it, the better it will work. If you vomit within 2 hours after taking the medication, call a health care professional to find out whether you should repeat the dose.
- Keep out of reach of children.
Advertisement
Related to this article
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Cancer diagnoses among civilians exposed to 9/11 dust keep rising, with strained health programs struggling to meet growing needs.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
4
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
5